Mark E. Davis Research Group California Institute of Technology |
||||||
Group Members - Graduate Student
 |
Jonathan Zuckerman Ph.D. student in Biochemistry and Molecular Biophysics, Caltech Office: Spalding Lab 29 |
Education: B.A. in Biophysics, Johns Hopkins University, 2006 Research Overview : My current work is focused on evaluating targeted nanoparticle delivery systems for small interfering RNA (siRNA) as therapeutics for kidney disease. This work involves understanding how properties of these nanoparticles (size, charge, targeting agents) affect their deliver to different regions of the kidney such as the glomerulus. I am also involved in work aimed at developing siRNA nanoparticles for the treatment of cancers. This work involves validation of new siRNA sequences against activating oncogenes in multiple cancer models and evaluation of different antibody targeting agents to enhance delivery of these nanoparticles to desired tumor regions. Publications: Rahman AM, Amin ARM, Wang Xu , Zuckerman JE, Choi CHJ, Zhou B, Wang S, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM. Systemic Delivery of siRNA-Nanoparticles Targeting RRM2 Suppresses Head and Neck Tumor Growth. Journal of Controlled Release in press Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. PNAS (2012) Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. PNAS. 108, 6656-6661 (2011) Tan FJ, Zuckerman JE, Wells RC, Hill RB. The c. elegans bcl-2 homolog ced-9 associates with and remodels lipid membranes. Protein Science. 2011 Jan;20(1):62-7460 Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. siRNA knockdown of ribonucleotide reducatase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest. Derm. 2011 Feb;131(2):453-60 Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20;8:39 Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010 Apr 15;464(7291):1067-70. Siskind LJ, Feinstein L, Yu T, Davis JS, Jones D, Choi J, Zuckerman JE, Tan W, Hill RB, Hardwick JM, Colombini M. Anti-apoptotic Bcl-2 Family Proteins Disassemble Ceramide Channels. J Biol Chem. 2008 Mar 14;283(11):6622-30
|
|